Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$65.179B
Market Cap
$1.05T
Net Income
$20.6B
Employees
50,000
Lilly reported 2025 revenue of $65.179 billion and net income of $20.640 billion. Revenue rose sharply from $45.043 billion in 2024 as demand for Mounjaro and Zepbound expanded.
Revenue Trend Analysis
YoY Change
+44.7%
4-Year CAGR
+23.2%
Peak Year
2025
Trend
Consistent Growth
Eli Lilly and Company has reported revenue across 5 fiscal years, compounding at +23.2% annually over 4 years. The most recent year saw a 44.7% increase versus the prior year. Revenue peaked in 2025 at $65.2B. Out of 4 reported periods, 4 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.2B | $20.6B | +44.7% |
| FY2024 | $45.0B | $10.6B | +32.0% |
| FY2023 | $34.1B | $5.2B | +19.6% |
| FY2022 | $28.5B | $6.2B | +0.8% |
| FY2021 | $28.3B | $5.6B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Driven by the absolute massive explosion of their diabetes and weight-loss drugs, Eli Lilly generates over $34 billion in annual revenue, with expectations for massive, historic growth in the coming years.
The obesity epidemic. Wall Street realized that Zepbound (weight loss) isn't just a drug; it is a massive lifestyle product that people will take forever. Investors aggressively bought the stock, propelling Eli Lilly to a staggering $700+ billion valuation, making it larger than Tesla.
A truly staggering amount. Eli Lilly routinely spends over $9 billion a year solely on R&D. Because 90% of experimental drugs completely fail in clinical trials, this massive spending is required to guarantee they find the next multi-billion dollar blockbuster.
Yes, incredibly profitable. Because the manufacturing cost of a chemical pill or injection is very low, the gross profit margins on a patented drug are absolutely astronomical, resulting in massive GAAP Net Income.
Yes. They are heavily considered a highly reliable 'Dividend Aristocrat'. Because of their massive, highly predictable cash flows from patented drugs, they have paid a consistently growing dividend for decades.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Eli Lilly and Company Revenue & Financials." CorpDigest, https://corpdigest.com/company/eli-lilly/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Eli Lilly and Company reported $65B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/eli-lilly/financials" target="_blank" rel="noopener">CorpDigest — Eli Lilly and Company financials</a></div>